Association of the Pro12ALA polymorphism of the PPAR-γ2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects

Metabolism: Clinical and Experimental

Volumn 52, Issue 2, 2003, Pages 213-217

  Niskanen, Leo ^a   Lindi, V ^a   Erkkila A ^a   Sivenius, K ^a   Luoma, J ^a   Yla Herttuala S ^a   Laakso, M ^a   Uusitupa, M I J ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALLELE; ANTIBODY BLOOD LEVEL; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM; REFERENCE VALUE; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0037302980     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2003.50039     Document Type: Article

References (46)

1. Auwerx J: PPARγ, the ultimate thrifty gene. Diabetologia 42: 1033-1049, 1999
2. Wu Z, Puigserver P, Spiegelman BM: Transcriptional activation of adipogenesis. Curr Opin Cell Biol 11:689-694, 1999
3. Fajas L, Auboeuf D, Raspé E, et al: The organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 272:18779-18789, 1999
4. Fajas L, Fruchart J-C, Auwerx J: PPARγ3 mRNA: A distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55-60, 1998
5. Sunvold H, Lien S: Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1. Biochem Biophys Res Commun 287;383-390, 2001
6. Auboeuf D, Rieusset J, Fajas L, et al: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alteration in adipose tissue of obese and NIDDM and patients. Diabetes 46:1319-1327, 1997
7. Ricote M, Huang J, Fajas L, et al: Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614-7619, 1998
8. Yen C-J, Beamer BA, Negri C, et al: Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: Identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun 241:270-274, 1997
9. Vigouroux C, Fajas L, Khallouf E, et al: Human peroxisome proliferator-activated receptor-γ2. Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 47:490-492, 1998
10. Valve R, Sivenius K, Miettinen R, et al: Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708-3712, 1999
11. Beamer BA, Yen C-J, Andersen RE, et al: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47:1806-1808, 1998
12. Cole SA, Mitchell BD, Hsueh W-C, et al: The Pro12Ala variant of peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 24:522-524, 2000
13. Meirhaeghe A, Fajas L, Helbecque N, et al: Impact of the peroxisome proliferator activated receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 24:195-199, 2000
14. Mori Y, Kim-Motoyama H, Katakura T, et al: Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 251:195-198, 1998
15. Mancini FP, Vaccaro O, Sabatino L, et al: Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 48:1466-1468, 1999
16. Ringel J, Engeli S, Distler A, et al: Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus. Biochem Biophys Res Commun 254:450-453, 1999
17. Clement K, Hercberg S, Passinge B, et al: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 24:391-393, 2000
18. Deeb SS, Fajas L, Nemoto M, et al: A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287, 1998
19. Masugi J, Tamori Y, Mori H, et al: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268:178-182, 2000
20. Koch M, Rett K, Maerker E, et al: The PPARγ2 amino acid polymorphism Pro12Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42:758-762, 1999
21. Hara K, Okada T, Tobe K, et al: The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216, 2000
22. Jacob S, Stumvoll M, Becker R, et al: The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32:413-416, 2000
23. Douglas JA, Erdos MR, Watanabe RM, et al: The peroxisome proliferator-activated receptor-gamma2Pro12Ala variant association with type 2 diabetes and trait differences. Diabetes 50:886-890, 2000
24. Kertsen S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405:421-424, 2000
25. Tontonoz P, Nagy L, Alvarez JGA, et al: PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidised LDL. Cell 93:241-252, 2000
26. Nagy L, Tontonoz P, Alvarez JGA, Chen H, et al: Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 93:229-240, 1998
27. Chawlaw A, Barak Y, Nagy L, et al: PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52, 2001
28. Steinberg D, Lewis A: Connor Memorial Lecture: Oxidative modification of LDL and atherogenesis. Circulation 95:1062-1071, 1997
29. Ylä-Herttuala S, Palinski ME, Rosenfeld ME, et al: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989
30. Palinski W, Rosnfeld ME, Ylä-Herttuala S, et al: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86:1372-1376, 1989
31. Roubey RAS: Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 39:1444-1454, 1996
32. Wu R, Nityanand S, Berglund L, et al: Antibodies against cardiolipin and oxidatively modified LDL in 50-year old men predict myocardial infarction. Arterioscler ThrombVasc Biol 17:3159-3163, 1997
33. Uusitupa M, Siitonen O, Aro A, et al: Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 28:22-26, 1985
34. Niskanen LK, Uusitupa MI, Sarlund H, et al: Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care 13:41-48, 1990
35. Uusitupa MIJ, Niskanen LK, Siitonen O, et at: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184, 1993
36. Niskanen L, Karjalainen J, Siitonen O, et al: Metabolic evolution of type 2 diabetes: A 10-year follow-up from the time of diagnosis. J Intern Med 236:263-270, 1994
37. World Health Organization Expert Committee on Diabetes Mellitus: Second Report. Technical Report Series No. 646. Geneva, Switzeland, WHO, 1970
38. Närvänen O, Erkkilä A, Ylä-Herttuala S: Evaluation and characterization of EIA measuring autoantibodies against oxidized LDL. Free Radic Biol Med 31:769-777, 2001
39. Lindi V, Sivenius K, Niskane L, et al; Effect of the Pro12Ala polymorphism of the PPAR2-gamma2 gene on long-term weight change in Finnish non-diabetic subject. Diabetologia 44:925-926, 2001
40. Erkkila AT, Narvanen O, Lehto S, et al: Autoantibodies against low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20:204-209, 2000
41. Stumvoll M, Wahl HG, Löblein K, et al: Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50: 876-881, 2001
42. Miyaoka K, Kuwasako T, Hirano K, et al: CD36 deficiency associated with insulin resistance. Lancet 357:686-687, 2001
43. Febbraio M, Abumrad NA, Hajjar DP, et al: A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 274:19055-19062, 1999
44. Sartippour MR, Renier G: Differential regulation of macrophage peroxisome proliferators-activated receptor by glucose. Role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. Arterioscler Thromb Vasc Biol 20:104-110, 2000
45. Neve BP, Fruchart JC, Staels B: Role of PPAR in atherosclerosis. Biochem Pharmacol 60:1245-1250, 2000
46. Uusitupa MIJ, Niskanen L, Luoma J, et al: Autoantibodies against oxidisex LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16:1236-1242, 1996